Arcellx

Historical price data

Arcellx is a mission-driven biotech founded in 2014 to advance humanity by engineering safer, more effective, and broadly accessible cell therapies. Its primary achievement is the development of a novel, fully synthetic D-Domain technology, which underpins its two therapeutic platforms: the single-infusion ddCAR and the dosable, controllable ARC-SparX system. The company's strategy leverages high-value partnerships, most notably a global collaboration with Kite Pharma, to accelerate the development and commercialization of its lead candidate, anito-cel, for relapsed/refractory multiple myeloma, while advancing a broader pipeline in hematologic malignancies, solid tumors, and autoimmune conditions.

Arcellx's core technology is the proprietary D-Domain, a fully synthetic binding scaffold that enables the development of its two main platforms: ddCAR (single-infusion CAR-T) and ARC-SparX (a dosable, controllable system using universal ARC-T cells and soluble SparX proteins).